Advertisement
UK markets close in 45 minutes

  • FTSE 100

    8,448.01
    +2.21 (+0.03%)
     

  • FTSE 250

    20,775.21
    -0.42 (-0.00%)
     

  • AIM

    792.62
    +1.01 (+0.13%)
     

  • GBP/EUR

    1.1653
    +0.0004 (+0.04%)
     

  • GBP/USD

    1.2662
    -0.0022 (-0.17%)
     

  • Bitcoin GBP

    52,264.57
    +1,465.89 (+2.89%)
     

  • CMC Crypto 200

    1,384.70
    -9.35 (-0.67%)
     

  • S&P 500

    5,319.84
    +11.69 (+0.22%)
     

  • DOW

    40,019.29
    +111.29 (+0.28%)
     

  • CRUDE OIL

    79.32
    +0.69 (+0.88%)
     

  • GOLD FUTURES

    2,380.70
    -14.20 (-0.59%)
     

  • NIKKEI 225

    38,920.26
    +534.53 (+1.39%)
     

  • HANG SENG

    19,376.53
    +302.82 (+1.59%)
     

  • DAX

    18,756.40
    -112.96 (-0.60%)
     

  • CAC 40

    8,200.07
    -39.92 (-0.48%)
     
money:

Best UK mortgage deals of the week

Find out the latest mortgage rates and deals from HSBC, NatWest, Santander, Barclays and more

Actavis in talks to buy Forest Labs for as much as $25 bln - WSJ

Reuters - UK Focus

Feb 17 (Reuters) - Actavis Plc (NYSE: ACT - news) is in advanced talks to acquire rival drug maker Forest Laboratories Inc (NYSE: FRX - news) in a deal that could value Forest at up to $25 billion, the Wall Street Journal reported citing people familiar with the matter.

The deal is expected to be announced as early as Tuesday, but it is possible that the talks could still fall apart, the Journal said. ()

Actavis and Forest Labs could not immediately be reached for comment by Reuters outside of regular business hours.